← All trials
NCT05624710
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2023
- Primary completion
- Oct 15, 2023
- Completion date
- Nov 23, 2023
- First posted
- Nov 22, 2022
- Last posted
- Nov 22, 2022
- Enrollment
- 30
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IncyteLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.